Royalty Payment Reduction. (a) In the event that Pieris is required to enter into a license or other agreement and pay a license fee or royalty to any Third Party for an Infringed Patent, the royalty payment described in Section 4.5 shall be reduced by the amount of such Third Party payment, up to fifty percent (50%) of the royalty payment for each calendar year. For the avoidance of doubt, in no event shall the royalty rate under Section 4.5 be reduced by more than fifty percent (50%) in any period.
Appears in 3 contracts
Sources: License and Transfer Agreement (Pieris Pharmaceuticals, Inc.), License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.), License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.)
Royalty Payment Reduction. (a) In the event that it becomes necessary for Pieris is required to enter into a license agreement, or other agreement agreement, and pay a license fee or royalty to any Third Party for an Infringed Patentdue solely to the inclusion of a First Antibody or Subsequent Antibody in a Product, the royalty payment described in Section 4.5 shall be reduced by the amount of such Third Party payment, up to fifty percent (50%) * of the royalty payment for each calendar year. For the avoidance of doubt, in no event shall the royalty rate under Section 4.5 be reduced by more than fifty percent (50%) * in any period.
Appears in 1 contract
Sources: License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.)